medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2013, Number 2

<< Back Next >>

Rev Esp Med Quir 2013; 18 (2)

Nonsteroidal Antiinflammatory Drugs as Risk Factor of Microscopic Hematuria in Prostate Transrectal Biopsy

Castellanos HH, Velázquez MRF, García-Villa PC, Navarro VJC, Figueroa ZM

Language: Spanish
References: 13
Page: 81-86
PDF size: 449.04 Kb.


ABSTRACT

Background: Prostate biopsy, is the only procedure to diagnose prostate cancer; however, complications may arise. Gross hematuria occurs in 50% of patients with a persistence of 3-7 days after the procedure. Although pre-surgical discontinuation of drugs that affect platelet function constitutes a routine practice, to our knowledge, there have been no studies showing that this practice is beneficial before ultrasound-guided prostatic transrectal biopsy.
Objective: To identify whether the use of nonsteroidal antiinflammatory drugs (NSAIDs) is a risk factor for gross hematuria after performing ultrasound-guided prostatic transrectal biopsy in patients with clinical suspicion of prostate cancer.
Material and method: A cohort study was done from July 1st 2009 to July 1st 2010 in which the association between the chronic use of NSAIDs and the prevalence of gross hematuria was assessed. Variables such as days with hematuria and chronic use of NSAIDs were obtained. Descriptive statistics was used and risk was determined with OR.
Results: Nonsteroidal antiinflammatory drugs use was not a risk factor for macroscopic hematuria after performing ultrasoundguided prostatic transrectal biopsy. We found an odds ratio of 0.74 with a confidence interval from 0.53 to 0.88 at 95% having no statistical significance.
Conclusions: In this study, the chronic use of NSAIDs was not a risk factor for gross hematuria.


REFERENCES

  1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005:16:481-488.

  2. Jemal A, Siegel R, Ward E, et al. Cancer statistic 2008. CA Cancer J Clin 2008;58:71-96.

  3. Mohar A, Frías-Mendivil M, Suchil-Bernal L, et al. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Pública Méx 1997;39:253-258.

  4. Dirección General de Epidemiología; SSA; Sistema Epidemiológico y Estadístico de las Defunciones, 2001 (Base de datos preliminar).

  5. Dirección General de Epidemiología; SSA; Compendio de Cáncer 2000.

  6. Jiménez-Ríos MA, Solares-Sánchez ME, Martínez-Cervera PF, et al. Onco-Guía Cáncer de próstata. Cancerología 2011;6:13-18.

  7. Levine MA, Ittman M, Melamed J, et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471-476.

  8. Emiliozzi P, Scarpone P, Depaula F, et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/mL: A randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 2004;171:197-199.

  9. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71.

  10. Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001;166:856-860.

  11. Rodríguez LV, Terris KM. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998;160:2115-2120.

  12. Luján GM, Páez BA, Fernández GI, et al. Efectos adversos de la biopsia prostática transrectal. Un análisis de 303 procedimientos. Actas Urol Esp 2001;25:46-49.

  13. Rodríguez-Patrón RR, Navas EE, Rodríguez-Navarro CQ, Mayayo DT. Meningitis por E. coli multirresistente tras biopsia transrectal ecodirigida. Actas Urol Esp 2003;27:305-307.




2020     |     www.medigraphic.com